Squarepoint’s RAPT Therapeutics RAPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-24,572
Closed -$832K 4834
2025
Q4
$832K Buy
+24,572
New +$763K ﹤0.01% 2764
2024
Q3
Sell
-13,499
Closed -$329K 4591
2024
Q2
$329K Buy
+13,499
New +$624K ﹤0.01% 3369
2022
Q1
Sell
-1,417
Closed -$416K 3391
2021
Q4
$416K Sell
1,417
-1,753
-55% -$469K ﹤0.01% 2267
2021
Q3
$787K Buy
3,170
+1,657
+110% +$438K ﹤0.01% 1704
2021
Q2
$385K Sell
1,513
-58
-4% -$10.8K ﹤0.01% 2337
2021
Q1
$279K Sell
1,571
-1,936
-55% -$319K ﹤0.01% 2462
2020
Q4
$554K Buy
+3,507
New +$763K ﹤0.01% 1741
2020
Q3
Sell
-26,502
Closed -$12.6M 2780
2020
Q2
$12.6M Buy
26,502
+24,174
+1,038% +$3.74M 0.2% 123
2020
Q1
$396K Buy
+2,328
New +$530K 0.01% 1160

Squarepoint's RAPT Position: Q1 2026 in Review

Squarepoint sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 24,572 shares — an estimated $832K sold.

Squarepoint first reported a position in RAPT in Q1 2020 and held it in 9 quarters. The position peaked at $12.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • Squarepoint reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 24,572 RAPT Therapeutics shares in Q1 2026, an estimated $832K.
  • Squarepoint first reported a position in RAPT Therapeutics in Q1 2020 and held it in 9 quarters.
  • Squarepoint's RAPT Therapeutics position peaked at $12.6M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.